Sanofi and J&J discontinued E.mbrace phase 3 study after the vaccine showed insufficient efficacy in preventing invasive E. coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

The oversubscribed series B financing was co-led by EQT Life Sciences and Sanofi Ventures, according to a Jan. 28 release. Existing investor F-Prime Capital also joined the round, with ...

The dynamic did not present equally across the country's regions: year-on-year growth in nominal prices was most pronounced in the cities of Northern Great Plain (15.6%), Southern Transdanubia (15.1%) ...

HealthDay News — The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ...

(HealthDay News) — The US Food and Drug Administration (FDA) has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 12,048.93 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...